Search Results for “HIV” – Page 29 – media

How common are flu shot side effects?

With fall well underway and winter just around the corner, chances are your doctor, pharmacist, and maybe even your mom are telling you it's time to roll up your sleeve for a flu shot. If you're inclined to ignore them, we get it: No one really enjoys being jabbed with a needle.
- Source: foxnews
- 506
- November 17, 2017
flu shot
‘Precision Medicine’ may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the world's more diverse populations, according to a study led by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, and the Keck School of Medicine of the University of Southern California (USC).
- Source: worldpharmanews
- 551
- November 6, 2017
cancer oncology precision medicine Researches
WHO report signals urgent need for greater political commitment to end tuberculosis

Global efforts to combat tuberculosis (TB) have saved an estimated 53 million lives since 2000 and reduced the TB mortality rate by 37%, according to the Global TB Report 2017, released by WHO today.
- Source: who
- 598
- October 31, 2017
Market Views tuberculosis WHO
CDC backs GSK’s Shingrix over Merck & Co’s Zostavax

Prospects for GlaxoSmithKline’s new shingle vaccine Shingrix have been raised after US advisors recommended that it should be used instead of rival Zostavax from Merck & Co.
- Source: Pmlive
- 924
- October 30, 2017
Company Insight HIV Shingrix Tivicay Triumeq vaccine
2nd Gulf Congress of Clinical Microbiology and Infectious Diseases (GCCMID)

2nd Gulf Congress of Clinical Microbiology and Infectious Diseases (GCCMID 2017) aims to provide with an enriching scientific and educational gathering in the region.
- Source: medical-events
- 705
- October 27, 2017
Exhibitions & Activities GCCMID 2017 infectious Microbiology
FDA awards 15 grants for clinical trials to stimulate product development for rare diseases

The U.S. Food and Drug Administration(FDA) announced that it has awarded 15 new clinical trial research grants totaling more than $22 million over the next four years to boost the development of products for patients with rare diseases. These new grants were awarded to principal investigators from academia and industry across the country.
- Source: fda.gov
- 618
- October 9, 2017
Clinical FDA rare diseases Researches
How to Write a Development Letter to Clients after an Exhibition

After attending Shanghai CNEF and Hospitalar in Brazil you come home and look at the pile of name cards and the masses of client information you collected. Now what? We often establish new business relationships at exhibitions such as these but the key of securing them lies in how you follow up on your clients. Ddu (www.drugdu.com), the leading global pharmaceutical and medical device B2B online platform, today shares with you some insight on how to organize client materials and write your first follow up development letter. I. Organize and follow up on your clients with purpose The first step is to collect as much information as possible and pay special attention to all the relevant details at the exhibition. For example, what the client is looking for, what they are most concerned about, what kind of products and suppliers they have in mind and which business partners they would like to keep. After this you will be able to arrange the information according to clients’ interests ...
- Source: Ddu
- 892
- September 18, 2017
Ddu College development letter
GSK opens new aluminium salts facility in Scotland

Being set to supply ingredients for around 400 million vaccines a year, a new £44 million aluminium salts facilityhas been officially opened by GlaxoSmithKline in Montrose, Scotland.
- Source: news.open-medical
- 622
- August 17, 2017
aluminium salt Company Insight HIV ingredient respiratory vaccine
Roche reports strong performance in the first half of 2017

Commenting on the Group’s results, Roche CEO Severin Schwan said: “In the first half of the year, both our Pharmaceuticals and Diagnostics Divisions showed strong performance, very much driven by new product launches. Particularly pleasing is the very successful launch of Ocrevus for the treatment of two forms of multiple sclerosis. Based on our half-year performance, we raised the outlook for the full-year to mid-single digit sales growth.”
- Source: www.roche.com
- 512
- August 4, 2017
Company Insight
GSK delivers further progress in Q2 and sets out new priorities for the Group

GSK delivers further progress in Q2 and sets out new priorities for the Group
- Source: www.gsk.com/
- 378
- August 4, 2017
Company Insight

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.